Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Esther Nakagawara

Optometrist Garner, NC Doctor of Optometry

NPI 1508171364 CMS profile 295425

958 Vandora Springs Rd, Garner, NC 27529

Open in the dashboard

General payments

$8,533

129 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$354,475 paid to institutions, not to them · program year 2025

Through program year 2025, Esther Nakagawara of Garner, NC is reported in the CMS Open Payments database as having received $8,533 across 129 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $354,475 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,445 14
2024 General $914 9
2023 General $1,916 21
2022 General $982 26
2021 General $738 19
2020 General $600 10
2019 General $1,937 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Esther Nakagawara
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Esther Nakagawara were reported at $1,445. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Esther Nakagawara Optometrist median Middle half National median
2019 $1,937 $159 $67–$371 $163
2020 $600 $72 $29–$165 $114
2021 $738 $125 $46–$292 $132
2022 $982 $162 $66–$374 $149
2023 $1,916 $177 $72–$406 $160
2024 $914 $188 $77–$427 $164
2025 $1,445 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $1,480 18 payments
  2. CooperVision Inc. $1,424 26 payments
  3. Alcon Vision LLC $1,061 13 payments
  4. Johnson & Johnson Vision Care, Inc. $918 28 payments
  5. Bausch & Lomb, a division of Bausch Health US, LLC $725 10 payments
  6. Dompe US, Inc. $328 4 payments
  7. Glaukos Corporation $315 2 payments
  8. Shire North American Group Inc $275 5 payments
  9. Tarsus Pharmaceuticals, Inc. $273 2 payments
  10. Oyster Point Pharma, Inc. $234 3 payments
  11. Other $1,499 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,777 121 payments
  2. Travel and Lodging $379 1 payment
  3. Entertainment $199 2 payments
  4. Consulting Fee $160 4 payments
  5. Gift $17 1 payment
Products named General payments · program years 2019–2025
  1. Acuvue $870 27 payments
  2. Multiple Brands Contact Lens $677 15 payments
  3. INFUSE $656 9 payments
  4. MIEBO $458 4 payments
  5. DAILIES $429 3 payments
  6. ULTRA $400 7 payments
  7. LOTEMAX SM $351 4 payments
  8. XIIDRA $333 3 payments
  9. OXERVATE $328 4 payments
  10. BIOTRUE ONE DAY $247 2 payments
  11. Other $4,847 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

15

Median for Optometry: 120

Drug cost

$117

Median for Optometry: $8,864

Branded share of claims

0%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Latanoprost Generic 15 $117

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Izervay
  • Astellas Pharma US Inc $125
$125 — —
OXERVATE
  • Dompe US, Inc. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record